CEUS LI-RADS 2017 and CT/MRI LI-RADS 2018 in liver tumor differential diagnosis

Objective: comparison of the effectiveness of using the Liver Imaging Reporting and Data System for CEUS (CEUS LI-RADS 2017) and for CT/MRI (CT/MRI LI-RADS 2018) in the diagnosis of liver tumors in patients with and without risk factors for hepatocellular carcinoma development. Retrospective analysis (based on morphological data) of the examination results of 165 patients with liver tumors (165 lesions) carried out. Group 1 included 61 patients with liver cirrhosis and chronic viral hepatitis B and C. Group 2 included 104 patients without risk factors for hepatocellular carcinoma. All patients underwent CEUS and CECT with the categorization according to CEUS LI-RADS 2017 and CT/MRI LI-RADS 2018 criteria. With the use of CEUS LI-RADS 2017 and CT/MRI LI-RADS 2018, the effectiveness in diagnosis of hepatocellular carcinoma (LR-4, LR-5) in high risk patients (group 1) was: sensitivity - 100.0%, specificity - 87.0%, and accuracy - 95.1% for CEUS; and 92.1%; 95.7%, and 93.4% for CECT. In the diagnosis of non-hepatocellular malignancy (LR-M) sensitivity, specificity, and accuracy for CEUS were 77.8%, 100.0%, and 96.7%; for CECT - 88.9%, 100.0%, and 98.4%. In patients with no risk factors (group 2) in the diagnosis of hepatocellular carcinoma CEUS showed sensitivity 100.0%, specificity 90.1%, and accuracy 91.3%; CECT - 100.0%, 72.5%, and 76.0%. In the diagnosis of non-hepatocellular malignancy sensitivity, specificity, and accuracy were 89.6%, 96.4%, and 93.3% for CEUS; 87.5%, 100.0%, and 94.2% for CECT. The use of LI-RADS systems allows standardizing the examination results interpretation in patients with high risk of hepatocellular carcinoma developing. The obtained results give the hope the updated system can be recommended for using in patients without risk factors for hepatocellular carcinoma.

ультразвуковое исследование с контрастным усилением (КУУЗИ), компьютерная томография с внутривенным контрастированием, CEUS LI-RADS, CT/MRI LI-RADS, гепатоцеллюлярная карцинома, contrast-enhanced ultrasound (CEUS), contrast-enhanced computed tomography, CEUS LI-RADS, CT/MRI LI-RADS, hepatocellular carcinoma

1. Бредер В.В., Балахнин П.В., Виршке Э.Р., Косырев В.Ю., Лазарев С.А., Ледин Е.В. Практические рекомендации по лекарственному лечению гепатоцеллюлярного рака // Злокачественные опухоли: Практические рекомендации RUSSCO. 2017. Т. 7. С. 339-351. Doi: 10.18027/2224-5057-2017-7-3s2-339-351.

2. Подымова С.Д. Болезни печени. М.: Медицина, 2006. 554 с.

3. London W.T., McGlynn K.A. Liver cancer // Cancer Epidemiology and Prevention. 3rd ed. / Ed. by D. Schottenfeld, J.F. Fraumeni Jr. NY: Oxford University Press, 2006. P. 763-786.

4. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma [published correction appears in J. Hepatol. 2012. V. 56. No. 6. P. 1430] // J. Hepatol. 2012. V. 56. No. 4. P. 908-943. Doi: 10.1016/j.jhep.2011.12.001.

5. GLOBOCAN 2008: cancer incidence and mortality worldwide / International Agency for Research on Cancer. World Health Organization. Режим доступа: // https://www.iarc.fr/news-events/globocan-2008-cancer-incidence-and-mortality-worldwide, свободный. Загл. с экрана. 20.10.2019.

6. Heimbach J.K., Kulik L.M., Finn R.S., Sirlin C.B., Abecassis M.M., Roberts L.R., Zhu A.X., Murad M.H., Marrero J.A. AASLD guidelines for the treatment of hepatocellular carcinoma // Hepatology. 2018. V. 67. No. 1. P. 358-380. Doi: 10.1002/hep.29086.

7. Roberts L.R., Sirlin C.B., Zaiem F., Almasri J., Prokop L.J., Heimbach J.K., Murad M.H., Moham med K. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis // Hepatology. 2018. V. 67. No. 1. P. 401-421. Doi: 10.1002/hep.29487.

8. Claudon M., Cosgrove D., Albrecht T., Bolondi L., Bosio M., Calliada F., Correas J., Darge K., Dietrich C, D’Onofrio M., Evans D., Filice C., Greiner L., Jager K., Jong N., Leen E., Lencioni R., Lindsell D., Martegani A., Meairs S., Nolsoe C.,Piscaglia F., Ricci P., Seidel G., Skjoldbye B., Solbiati L., Thorelius L., Tranquart F., Weskott H., Whittingham T. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008 // Ultraschall Med. 2008. V. 29. No. 1. P. 28-44. Doi: 10.1055/s-2007-963785.

9. Bruix J., Sherman M.; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma // Hepatology. 2005. V. 42. No. 5. P. 1208-1236. Doi: 10.1002/hep.20933.

10. Omata M., Lesmana L., Tateishi R., Chen P., Lin S., Yoshida H., Kudo M., Lee J., Choi B., Poon R., Shiina S., Cheng A., Jia J., Obi S., Han K., Jafri W., Chow P., Lim S., Chawla Y., Budihusodo U., Gani R., Lesmana C., Putranto T., Liaw Y., Sarin S. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carci noma // Hepatol. Int. 2010. V. 4. No. 2. P. 439-474. Doi: 10.1007/s12072-010-9165-7.

11. Kudo M., Izumi N., Kokudo N., Matsui O., Sakamoto M., Nakashima O., Kojiro M., Makuuchi M., Kudo M., Izumi N., Kokudo N. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version // Dig. Dis. 2011. V. 29. No. 3. P. 339-364. Doi: 10.1159/000327577.

12. Катрич А.Н., Рябин Н.С., Польшиков С.В. Ультразвуковое исследование с контрастным усилением в диагностике гепатоцеллюлярной карциномы у пациентов с циррозом печени и без него // Ультразвуковая и функциональная диагнос тика. 2018. № 4. С. 17-32.

13. Santillan C. LI-RADS enables standardized interpretation, reporting of HCC // RSNA News. 2012. V. 22. No. 2. P. 13-14. Режим доступа: // https://ektron.rsna.org/uploadedFiles/RSNA/Content/News/PDF/2012_RSNA_News_PDFs/002%20RSNA_News_February2012_Low_Res.pdf, свободный. Загл. с экрана. 20.10.2019.

14. Napel S.A., Beaulieu C.F., Rodriguez C., Cui J., Xu J., Gupta A., Korenblum D., Greenspan H., Ma Y., Rubin D.L. Automated retrieval of CT images of liver lesions on the basis of image similarity: method and preliminary results // Radiology. 2010. V. 256. No. 1. P. 243-252. Doi: 10.1148/radiol.10091694.

15. Schwartz L.H., Panicek D.M., Berk A.R., Li Y., Hricak H. Improving communication of diagnostic radiology findings through structured reporting // Radiology. 2011. V. 260. No. 1. P. 174-181. Doi: 10.1148/radiol.11101913.

16. CT/MRI LI-RADS v2018 Core / American College of Radiology. Режим доступа: // https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en, свободный. Загл. с экрана. 20.10.2019.

17. Kono Y., Lyshchik A., Cosgrove D., Dietrich C., Jang H., Kim T., Piscaglia F., Willmann J., Wilson S., Santillan C., Kambadakone A., Mitchell D., Vezeridis A., Sirlin C. Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS®): the official version by the American College of Radiology (ACR) // Ultraschall Med. 2017. V. 38. No. 1. P. 85-86. Doi: 10.1055/s-0042-124369.

18. Piscaglia F., Wilson S.R., Lyshchik A., Cosgrove D., Dietrich C., Jang H., Kim T., Salvatore V., Willmann J., Sirlin C., Kono Y. American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay // Ultraschall Med. 2017. V. 38. No. 3. P. 320-324. Doi: 10.1055/s-0042-124661.

19. CEUS LI-RADS v2017 Core / American College of Radiology. Режим доступа: // https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUSLI-RADS-2017-Core.pdf?la=en, свободный. Загл. с экрана. 20.10.2019.

20. Weskott H.-P. Контрастная сонография. Бремен: UNI-MED, 2014. 284 c.

21. Claudon M., Dietrich C.F., Choi B.I., Cosgrove D.O., Kudo M., Nolsoe C.P., Piscaglia F., Wilson S.R., Barr R.G., Chammas M.C., Chaubal N.G., Chen M.H., Clevert D.A., Correas J.M., Ding H., Forsberg F., Fowlkes J.B., Gibson R.N., Goldberg B.B., Lassau N., Leen E.L., Mattrey R.F., Moriyasu F., Solbiati L., Weskott H.P., Xu H.X. Клинические рекомендации по ультразвуковому исследованию печени с применением контрастных препаратов. Пересмотр от 2012 г. Инициатива WFUMB-EFSUMB с представительством AFSUMB, AIUM, ASUM, FLAUS и ICUS // Ультра звуковая и функциональная диагностика. 2017. № 1. C. 81-116.

22. Королюк И.П. Медицинская информатика: Учебник. Изд. 2-е, перераб. и доп. Самара: Офорт, 2012. 244 с.

23. Willatt J.M., Hussain H.K., Adusumilli S., Marrero J.A. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies // Radiology. 2008. V. 247. No. 2. P. 311-330. Doi: 10.1148/radiol.2472061331.

24. Hussain S.M., Reinhold C., Mitchell D.G. Cirrhosis and lesion characterization at MR imaging // Radiographics. 2009. V. 29. No. 6. P. 1637-1652. Doi: 10.1148/rg.296095508.

25. Катрич А.Н., Порханов В.А. Ультразвуковое исследование с контрастным усилением в дифференциальной диагностике очаговых новообразований печени // Хирургия. Журнал им. Н.И. Пи рогова. 2019. № 6. С. 49-59. Doi: 10.17116/hirurgia201906149.

26. Yen Y.H., Wang J.H., Lu S.N., Chen T.Y., Changchien C.S., Chen C.H., Hung C.H., Lee C.M. Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia // Eur. J. Radiol. 2006. V. 60. No. 3. P. 439-444. Doi: 10.1016/j.ejrad.2006.06.007.

27. Strobel D., Bernatik T., Blank W., Schuler A., Greis C., Dietrich C.F., Seitz K. Diagnostic accuracy of CEUS in the differential diagnosis of small (≤20 mm) and subcentimetric (≤10 mm) focal liver lesions in comparison with histology. Results of the DEGUM multicenter trial // Ultraschall Med. 2011. V. 32. No. 6. P. 593-597. Doi: 10.1055/s-0031-1271114.

28. Катрич А.Н., Рябин Н.С., Польшиков С.В., Катрич Н.А. Ультразвуковое исследование с контрастным усилением в дифференциальной диагностике фокально-нодулярной гиперплазии и ге патоцеллюлярной аденомы печени // Кубанский научный медицинский вестник. 2019. Т. 26. № 2. С. 50-63. Doi: 10.25207/1608-6228-2019-26-2-50-63.

29. Jha R.C., Mitchell D.G., Weinreb J.C., Santillan C.S., Yeh B.M., Francois R., Sirlin C.B. LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas // AJR. 2014. V. 203. No. 1. P. W48-W69. Doi: 10.2214/AJR.13.12169.

30. Grant A., Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology // Gut. 1999. V. 45. Suppl. 4. P. IV1-IV11. Doi: 10.1136/gut.45.2008.iv1.

31. Alvarez M., Romeiro F. What should be done for patients with liver lesions in the LI-RADS 2 and 3 categories? // AME Med. J. 2019. No. 4. P. 17. Doi: 10.21037/amj.2019.02.04.

32. Ronot M., Fouque O., Esvan M., Lebigot J., Aube C., Vilgrain V. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm // J. Hepatol. 2018. V. 68. No. 4. P. 715-723. Doi: 10.1016/j.jhep.2017.12.014.

33. Schellhaas B., Wildner D., Pfeifer L., Goertz R., Hagel A., Neurath M., Strobel D. LI-RADS-CEUS - proposal for a contrast-enhanced ultrasound algorithm for the diagnosis of hepatocellular carcinoma in high-risk populations // Ultraschall Med. 2016. V. 37. No. 6. P. 627-634. Doi: 10.1055/s-0042-112221.

34. Alhasan A., Cerny M., Olivie D., Billiard J.S., Bergeron C., Brown K., Bodson-Clermont P., Castel H., Turcotte S., Perreault P., Tang A. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features // Abdom. Radiol. (NY). 2019. V. 44. No. 2. P. 517-528. Doi: 10.1007/s00261-018-1762-2.

35. Chen L.D., Ruan S.M., Lin Y., Liang J.Y., Shen S.L., Hu H.T., Huang Y., Li W., Wang Z., Xie X.Y., Lu M.D., Kuang M., Wang W. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS // Eur. Radiol. 2019. V. 29. No. 8. P. 4249-4257. Doi: 10.1007/s00330-018-5927-8.

36. Schellhaas B., Gortz R.S., Pfeifer L., Kielisch C., Neurath M.F., Strobel D. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS // Eur. J. Gastroenterol. Hepatol. 2017. V. 29. No. 9. P. 1036-1044. Doi: 10.1097/MEG.0000000000000916.

37. Erkan B., Meier J., Clark T.J., Kaplan J., Lambert J.R., Chang S. Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC // PLoS One. 2019. V. 14. No. 2. P. e0226291. Doi: 10.1371/journal.pone.0226291.

38. Strobel D., Seitz K., Blank W., Schuler A., Dietrich C., von Herbay A., Friedrich-Rust M., Kunze G., Becker D., Will U., Kratzer W., Albert F.W., Pachmann C., Dirks K., Strunk H., Greis C., Bernatik T. Contrast-enhanced ultrasound for the characterization of focal liver lesions - diagnostic accuracy in clinical practice (DEGUM multicenter trial) // Ultraschall Med. 2008. V. 29. No. 5. P. 499-505. Doi: 10.1055/s-2008-1027806.

39. Westwood M., Joore M., Grutters J., Redekop K., Armstrong N., Lee K., Gloy V., Raatz H., Misso K., Severens J., Kleijnen J. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterization of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis // Health Technol. Assess. 2013. V. 17. No. 16. P. 1-243. Doi: 10.3310/hta17160.